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Abstract
Background: Chagas disease (CD) continues to be a neglected infectious disease with one of the largest burdens globally.
Despite the modest cure rates in adult chronic patients and its safety profile, benznidazole (BNZ) is still the drug of choice. Its
current recommended dose is based on nonrandomized studies, and efficacy and safety of the optimal dose of BNZ have
been scarcely analyzed in clinical trials.
Methods/design: MULTIBENZ is a phase II, randomized, noninferiority, double-blind, multicenter international clinical trial. A
total of 240 patients with Trypanosoma CD in the chronic phase will be recruited in four different countries (Argentina, Brazil,
Colombia, and Spain). Patients will be randomized to receive BNZ 150mg/day for 60 days, 400mg/day for 15 days, or 300
mg/day for 60 days (comparator arm). The primary outcome is the efficacy of three different BNZ therapeutic schemes in
terms of dose and duration. Efficacy will be assessed according to the proportion of patients with sustained parasitic load
suppression in peripheral blood measured by polymerase chain reaction. The secondary outcomes are related to
pharmacokinetics and drug tolerability. The follow-up will be 12months from randomization to end of study participation.
Recruitment was started in April 2018.
Conclusion: This is a clinical trial conducted for the assessment of different dose schemes of BNZ compared with the standard
treatment regimen for the treatment of CD in the chronic phase. MULTIBENZ may help to clarify which is the most adequate
BNZ regimen in terms of efficacy and safety, predicated on sustained parasitic load suppression in peripheral blood.
Trial registration: ClinicalTrials.gov, NCT03191162. Registered on 19 June 2017.
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Introduction
Chagas disease (CD) is a neglected parasitic infection
caused by the protozoan Trypanosoma cruzi. It is en-
demic in the American continent, and according to the
latest estimates, it affects around 6 million people. Thir-
teen percent of the Latin American population remains
at risk of contracting the infection, which is transmitted
to humans by Triatominae insects [1]. CD has also be-
come a rising health problem in nonendemic countries
because of international migration, and nonvectorial
transmission can occur trhough blood transfusion, organ
transplant, and congenital infection [2, 3]. In addition,
orally transmitted CD has been detected in endemic
areas because of food carrying either infected Triatomi-
nae insects or their feces [4].
After malaria and schistosomiasis, CD represents the
third largest parasitic disease burden globally, with more
than 15,000 deaths attributed directly to chronic Chagas
cardiomyopathy (CCM) annually. CCM is the main
complication in the chronic phase of CD, and it develops
in approximately 30% of patients chronically infected
with T. cruzi [1]. Moreover, it is the most common form
of nonischemic cardiomyopathy in Latin America [5, 6].
Currently, there are only two available drugs to treat CD:
nifurtimox and benznidazole (BNZ). Of these two, BNZ is the
one most studied and most often used as a treatment. How-
ever, current schemes of this treatment have some limitations.
On the one hand, it has a limited efficacy based on serocon-
version (around 50–80% in the acute phase of the disease and
8–20% in the chronic phase) [7]. Another important limitation
is the high rate of adverse events (AEs) when using these
drugs. The incidence of AEs related to BNZ varies from 40–
50% up to 98%, and around 15% of these patients have to de-
finitively stop the treatment for this reason, with the rate even
higher in patients treated with nifurtimox [8–10]. The most
commonly observed AEs are hypersensitivity (rash, fever, gen-
eralized edema, lymphadenopathy, myalgia, and arthralgia),
gastrointestinal disorders, bone marrow toxicity (neutropenia
and thrombocytopenic purpura), and peripheral polyneurop-
athy [9]. Current knowledge about the BNZ toxicity mecha-
nisms is scarce because the main studies have focused on the
clinical aspects of these AEs [10]. Our group recently carried
out an analysis of the cytokine profile and human leukocyte
antigen (HLA) classes I and II of patients who were treated
with BNZ, and we found a higher treatment discontinuation
rate due to skin hypersensitivity AEs in patients who had the
HLA-B*3505 allele [11].
Moreover, another drawback of the studies assessing the
efficacy of BNZ in chronic CD is the lack of a biomarker
to define the cure of disease. Currently, the cure criteria
are negative seroconversion of two serologic assays against
different antigens, but it usually takes several years after
an effective treatment, precluding its use in clinical trials.
In addition, detection of T. cruzi DNA in peripheral blood
cannot be used to define cure, because a negative result
does not mean absence of the infection; however, in recent
years, it has become an important tool used to identify
therapeutic failure when the result remains positive after
completed treatment [8].
Antitrypanosomal treatment is always recommended for
acute and congenital CD, reactivated CD infections, and
chronic CD in individuals younger than 18 years of age [3,
12]. Despite the limitations of treatment of chronic CD in
adults, international guidelines recommend treatment with
either BNZ or nifurtimox in patients under 50 years old with
nonestablished cardiac complications [13, 14]. This is based
mainly on the lower long-term clinical progression observed
in patients treated with BNZ after a mean follow-up of 10
years, the parasite persistence and concomitant chronic in-
flammation underlying CCM, and the prevention of vertical
transmission to children born by infected women and
treated before pregnancy [3, 15]. Results of a systematic re-
view and meta-analysis showed little benefit of the treatment,
and the BENEFIT (Evaluation of the Use of Antiparasital
Drug [Benznidazole] in the Treatment of Chronic Chagas’
Disease) trial found no statistically significant reduction of
cardiac clinical impairment in patients with moderate to se-
vere cardiomyopathy [16, 17]. Treatment should be individu-
alized for patients older than 50 years of age and for patients
with comorbidities [3].
BNZ dosing and duration
Currently, the recommended BNZ dosage and duration
regimen for CD treatment is 5–7 mg/kg/day for 60 days.
This recommendation is based on studies carried out in
the 1970s [18]. However, nowadays, both the dose and
duration of treatment are under discussion, predicated
in findings from CD murine models, pharmacokinetic
(PK)/pharmacodynamic studies, and studies in patients
who discontinued the treatment. On this basis, it seems
clear that BNZ dose may be optimized.
Lower dose
Two population PK studies have shown through mathem-
atical models that lower dosage with the same duration
would have the same efficacy [19, 20]. One of them [19]
was carried out in children and the other in adults [20]. In
the pediatric study, children were treated with a standard
dose of BNZ. Although significantly lower concentrations
of the drug were achieved compared with those reported
in adults, the treatment was effective in all patients who
completed the treatment course. Moreover, data from a
second study carried out in adults revealed that a dose of
5mg/kg/day might lead to overexposure in the majority of
patients and that a BNZ dose of 2.5 mg/kg/day is enough
to adequately keep BNZ trough plasma concentrations
within the recommended target range according to previ-
ous PK studies [21, 22].
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Higher dose
Recent in vitro assays that quantify the time necessary to
eliminate the parasites (time-to-kill assays) showed that
nitroheterocyclic compounds such as BNZ are dose-
dependent [23]. In fact, treatment schemes with a higher-
than-standard dose of BNZ (400mg daily) with the same
duration already have been used (STOP-CHAGAS [A
Study of the Use of Oral Posaconazole in the Treatment
of Asymptomatic Chronic Chagas Disease] study), without
observing a higher proportion of side effects [24]. Further-
more, another study of 54 patients treated with BNZ tried
to establish a correlation between the serum concentra-
tions of the drug and the appearance of AEs. Fifty-three
patients (98%) experienced at least one AE during follow-
up, but no relationship was found between the drug serum
concentration and the occurrence of AEs [25].
Shorter regimens
Finally, regarding the duration of treatment, recent stud-
ies in animal models have shown that shorter schemes
(25% of standard duration) achieve the same cure rate
[26]. This is under assessment in other clinical trials [27,
28], but findings of one study showed an important cure
rate in patients who had to abandon the treatment due
to severe adverse events (SAEs) [29].
Methods/design
The MULTIBENZ study (Evaluation of Different Benzni-
dazole Regimens for the Treatment of Chronic Chagas
Disease; ClinicalTrials.gov, NCT03191162) is a phase II,
noninferiority, parallel-arm, randomized, double-blind,
multicenter international clinical trial assessing the effi-
cacy and safety of three different BNZ dose schemes for
the treatment of CD in chronic phase. It will be carried
out in four different countries: Argentina, Brazil,
Colombia, and Spain (protocol version V1/05-12-2016).
Outcomes and endpoints
The primary objective of MULTIBENZ is to evaluate the ef-
ficacy of different BNZ regimens at 12months after
randomization in patients with CD in the chronic phase.
The primary efficacy outcome is defined as the proportion of
patients with sustained parasitic load suppression in periph-
eral blood measured by polymerase chain reaction (PCR)
during the first 12months of follow-up after randomization.
The secondary objectives are to evaluate the parasitic
kinetics by detecting parasitic DNA measured by PCR in
peripheral blood at different time points (weeks 1, 2, 4,
and 8 during the treatment period and in the fourth,
sixth, and eighth months after the start of treatment), to
evaluate the serological response by enzyme-linked im-
munosorbent assay (ELISA) methods at the end of
follow-up (month 12), to assess the tolerability and
safety of the different BNZ regimens, to correlate BNZ
levels with the therapeutic response and AEs, to correl-
ate the presence of HLA-B*3505 with the presence of se-
vere AEs, and to correlate the different discrete typing
units of T. cruzi with the therapeutic response.
Primary endpoints
The primary endpoint is parasitologic response, defined
as maintained negative qualitative PCR results during
the 12-month follow-up period. For efficacy assessments,
the end of treatment of each treatment arm will be de-
fined in accordance with the duration of the treatment
regimen. Incidence and severity of AEs and those lead-
ing to treatment discontinuation will also be recorded.
Secondary endpoints
Secondary endpoints are parasitic clearance at weeks 1,
2, 4, and 8 during the treatment period and at 4, 6, and
8 months during the follow-up period, measured by
qualitative PCR. Serological response will be assessed by
conventional serology at 12-month follow-up. The pro-
portion of HLA-B*3505 carriers among the patients who
experience SAEs will be recorded, as will blood concen-
trations of BNZ at 15 d and by the end of treatment.
Patient eligibility
Patients aged ≥ 18 years having any combination of at
least two positive serologic test results against T. cruzi
(indirect immunofluorescence, indirect
hemagglutination, or ELISA) and not having previously
received treatment with BNZ or nifurtimox (either com-
pletely or partially) will be eligible. Inclusion and exclu-
sion criteria are summarized in Tables 1 and 2,
respectively.
Randomization and follow-up
Patients are randomly assigned to receive BNZ 150mg/
day for 60 days, 400 mg/day for 15 days, or the standard
scheme of 300 mg/day for 60 days. Because this is a
double-blind trial, investigators and all sponsor staff will
not be aware of the treatment allocation and
randomization list until the end of the trial. Double-
blinding will be adopted for all trial arms. Patients will
be randomized 1:1:1, and randomization will be done via
a remote and interactive response system, according to a
predefined list. To avoid bias, randomization will be cen-
tralized and concealed. The treatment groups will be al-
located on day 1 on the basis of a balanced block
randomization, taking into account the country. Each
patient will be assigned an identification code that will
correspond to the trial kit number allocated to the pa-
tient. The label will indicate the trial number and the
number of the kit, but it will not indicate the treatment
designation.
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Scheduled follow-up visits will occur at 7, 15, 28, and
60 days and up to 4, 6, 8, and 12months after initiation
of treatment. More information is provided in Fig. 1.
Sample size and data analysis
For the sample size calculation, we considered a nonin-
feriority design for two-sample comparison of propor-
tions. Assumption of a noninferiority margin of 10% in
relation to standard treatment, which represents a re-
duction of 50% of the total number of patients who ei-
ther have a positive PCR result during follow-up or have
to discontinue the treatment due to AEs, has been taken
into account as a hypothesis. It is estimated that in the
standard arm of treatment, 40% of patients will be evalu-
ated as treatment failures according to the intention-to-
treat principle.
For a unilateral type I error (p = 0.025) and a power of
80%, a comparison between four groups, an effect size of
0.067, and an average proportion of 0.75 with a variance
of 0.013, 204 individuals would be needed. Considering
a rate of 15% defaulted patients, the total number of pa-
tients that should be included in the study is 240, which
will comprise 60 participants per country.
The categorical data will be presented as absolute
numbers and proportions, and the continuous variables
will be expressed as means and standard deviations
when normal distribution is demonstrated (using the
Kolmogorov-Smirnov test) or as medians and interquar-
tile ranges when it is not.
For comparison of the distribution of categorical vari-
ables, the χ2 test or Fisher’s exact test will be used, and
the Mann-Whitney U test or Student’s t test will be used
for continuous variables, respectively, depending on the
presence or not of normal distribution.
A comparative analysis of the main clinicoepidemiologi-
cal variable among the three groups will be carried out.
The primary efficacy analysis will be the comparison of
the proportion of patients with sustained parasitologic
clearance of each treatment arm compared with the stand-
ard arm of treatment. The time until the first positive PCR
result for T. cruzi will be evaluated by Kaplan-Meier sur-
vival analysis with the log-rank test for significance.
The proportion of patients with SAEs and/or AEs
leading to treatment discontinuation will be described
per trial arm and by System Organ Class (using pre-
ferred terms defined by MedDRA 13.1), according to the
National Cancer Institute’s Common Terminology Cri-
teria for Adverse Events (version 4.03). Incidence rate
and 95% confidence interval will be presented per trial
arm for SAEs and AEs per category, along with the most
frequent AEs.
Safety laboratory parameters (hematology and bio-
chemistry) will also be described individually per trial
arm, showing the proportion of patients by degree of
Table 1 Inclusion criteria
Inclusion criteria (patients should meet all criteria)
• Adults ≥ 18 years old
• Have been diagnosed with Chagas disease by two positive serological
tests using different antigens
• Have detectable Trypanosoma cruzi DNA in peripheral blood through a
qualitative interpretation of the polymerase chain reaction technique
• Written informed consent provided
• Weight≥ 50 kg and≤ 80 kg
• Ability to comply with all tests and specified protocol visits and have a
permanent address
• Patients must be residents of areas free of vector transmission
(Triatoma infestans), defined by local health programs or by the Pan
American Health Organization/World Health Organization definition.
• Women of childbearing age should have a urine or serum negative
pregnancy test at the moment of the baseline visit. Breastfeeding
should not be allowed, and a barrier method of contraception should
be used during the treatment phase.
Table 2 Exclusion criteria
Exclusion criteria
• Having previously received treatment with benznidazole or nifurtimox
(either completely or incompletely)
• Signs and/or symptoms of severe cardiac form of Chagas disease (as
confirmed by local national guidelines)
• Impossibility to complete the specified protocol follow-up visits
• Acute or chronic health problems that, in the opinion of the principal
investigator, may interfere with the evaluation of the efficacy and/or
safety related to the drug (for example, acute infections, human
immunodeficiency virus infection, liver or kidney disease)
• History of alcohol abuse
• Known hypersensitivity to metronidazole drugs
• Concomitant use or history of use of allopurinol, antimicrobial,
antiparasitic, or antifungal agents
• Having laboratory parameters outside the range of normal or that are
considered clinically relevant by the responsible physician:
Total leukocyte count must be within the normal range, with an
acceptable range of ± 5%.
Total platelet count must be within the normal range up to 550,
000/mm3 or 550 × 109/L.
Total bilirubin must be within the normal range.
Transaminase levels must be within the normal range, with an
acceptable range of 25% above the upper limit of normal (ULN).
Total creatinine level must be within the normal range, with an
acceptable variation of 10% above the ULN.
Alkaline phosphatase level must be within the normal range up to
< 2.5× ULN.
Gamma glutamyl transferase level must be within the normal
range up to 2× ULN.
Fasting glucose must be within the normal range.
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elevation relative to upper limit of normal and baseline
values, as well as blood level changes over time.
Safety data will be correlated to efficacy and treatment
compliance data and to PK parameters. Differences in
the rate of absorption in serology will be estimated with
t test pairs or the Wilcoxon test, depending on their dis-
tribution. All safety analyses will be carried out on all
patients treated, understood as all patients who receive
at least one dose of treatment. Finally, the sensitivity,
specificity, and positive and negative predictive values of
the presence of HLA-B*3505 and their relationship with
the occurrence of SAEs will be calculated.
The efficacy analysis will be carried out according to the
intention-to-treat principle. The group of patients analyzed
will be all randomized patients in each of the treatment
branches. Cases lost during follow-up and dropouts will be
considered treatment failures.In addition, a per-protocol
analysis will be defined as all patients receiving randomized
treatment who meet the main criteria, have not perman-
ently left the administration of the treatment, and have no
other protocol deviation. Patients lost to follow-up will be
excluded unless they present a positive PCR result, in which
case, they will be included in the analysis. The results will
be analyzed using IBM SPSS Statistics version 19.0 software
(IBM Corp., Armonk, NY, USA).
Laboratory procedures
Serology
Two different anti–T. cruzi serologic tests based on dif-
ferent antigens were used for assessing patient eligibility.
To avoid interlaboratory variability, serum samples col-
lected at the times indicated in the protocol will be sent
at the end of the study to a centralized laboratory that
will process them using two techniques in parallel:
Architect Chagas (Abbott Laboratories, Wiesbaden,
Germany) and ORTHO Trypanosoma cruzi ELISA Test
System (Ortho Clinical Diagnostics, Raritan, NJ, USA).
In order to give greater robustness to the results, sam-
ples from external quality control sent by the National
Program of Quality Control of Brazil will be included.
PCR
Laboratories included in the project will carry out the same
reverse transcriptase (RT)-PCR protocol following the in-
structions included in the laboratory manual agreed among
all of them. To carry out this technique, 5ml of whole blood
will be collected and mixed with 5ml of guanidine hydro-
chloride 6M–ethylenediaminetetraacetic acid 0.2M for a
minimum of 72 h at room temperature. Three DNA extrac-
tions will be performed using the manual column method
(High Pure PCR Template Preparation Kit; Roche Diagnos-
tics, Mannheim, Germany), except in Spanish centers (Vall
d´Hebron University Hospital and Ramón y Cajal University
Hospital) where DNA extraction will also be done in tripli-
cate using an automated extraction method (NucliSens easy-
MAG, bioMèrieux, Marcy l’Etoile, France).The consensual
PCR protocol consists of a real-time multiple PCR (Duffy
et al. 2013) [30] that allows the amplification of a T. cruzi sat-
ellite DNA region and a linearized recombinant plasmid
used as an internal amplification control. The RT-PCR will
be carried out in duplicate from each of the extractions. At
least one amplification of the six performed with an amplifi-
cation cycle (cycle threshold) of T. cruzi below 40 and a cor-
rect value of Internal Amplification Control (IAC) will be
interpreted as positive. To be correct, the values of the IAC
must meet Tukey’s criteria.
To assess the homogeneity of the results obtained by the
different laboratories, a harmonization panel consisting of
ten tubes containing blood with uninfected guanidine and
infected with 1, 10, and 100 parasitic equivalents per milliliter
of T. cruzi strains TcV and TcVI was processed. The samples
were processed blindly by the different laboratories, and the
results were evaluated by an external center in charge of
providing the panel and analyzing the results (Instituto de
Investigaciones en Ingeniería Genética y Biología Molecular,
Buenos Aires, Argentina). On the other hand, and following
the same work scheme, four external quality control panels
will be analyzed during the study period.
HLA typing
The typing of HLA-B alleles is carried out from the
dried blood samples on paper (dried blood spots [DBS]).
Fig. 1 Clinical trial design. BNZ Benznidazole, BV Baseline visit, EoF End of follow-up, FV Follow-up visit, SV Screening visit, TV Treatment visit
Molina-Morant et al. Trials          (2020) 21:328 Page 5 of 10
For this purpose, DNA is extracted using DNA Elution
Solution reagent (catalog no. 159994; Qiagen, Carpin-
teria, CA, USA), and the concentration and quality are
evaluated by measuring the absorbance at 260 and 280
nm using the Colibri microvolume spectrometer (Titer-
tek-Berthold, Pforzheim, Germany). The characterization
of the HLA-B alleles is carried out by PCR sequence-
specific oligonucleotide (SSO) (Luminex Corp., Austin,
TX, USA), following the instructions of the Lifecodes
HLA typing kit (Immucor; Diagnóstica Longwood, Zara-
goza, Spain). Briefly, the PCR-SSO/Luminex consists of
amplification with biotinylated primers of the most poly-
morphic regions of the HLA-B gene, followed by
hybridization of the amplified product with specific
probes for each allele located on the surface of Luminex
microspheres and revealed with conjugated streptavidin
with phycoerythrin. Finally, it is analyzed using an
xMAP100 fluoroanalyzer (Luminex Corp.).
BNZ serum concentration
Quantification of BNZ is done from dried blood samples
on paper (DBS). The quantification is performed by li-
quid chromatography (ACQUITY ultra performance li-
quid chromatography high-strength silica T3 C18, 2.1 ×
50 mm; Waters, Milford, MA, USA) coupled to triple-
quadrupole mass spectrophotometry (Xevo TQ; Waters).
Study organization
The MULTIBENZ study network includes four countries
and seven centers, with the Spanish coordinating center
located at Vall d’Hebron University Hospital in Barce-
lona, Spain. The study contemplates a total of three
stages, which are outlined below.
1. Recruitment sites
Countries involved in the recruitment will be Spain
(University Hospital Vall d’Hebron, Barcelona; University
Hospital Ramón y Cajal, Madrid), Argentina (Instituto
Nacional de Parasitología Dr. Mario Fatala Chaben, Buenos
Aires; Instituto de Cardiología Juana Francisca Cabral,
Corrientes), Brazil (Centro de Pesquisas René Rachou –
Fundação Oswaldo Cruz, Belo Horizonte; Hospital Univer-
sitário Clemente de Faria, Montes Claros), and Colombia
(Fundación Cardioinfantil – Instituto de Cardiología).
2. Selection phase
Patients with CD in the chronic phase who come to
the study centers will be evaluated in order to assess if
they meet the inclusion criteria. For those who agree to
participate and sign the informed consent, detection of
parasitic DNA by PCR in peripheral blood will be per-
formed. Patients with a PCR result negative for T. cruzi
will be withdrawn from the study. The screening proced-
ure must occur up to 90 days or less before the initiation of
treatment. Serology and DNA determination by PCR will be
accepted as valid and will not need to be repeated if a posi-
tive result was obtained in a previous period of 3months.
All patients will undergo a clinical history and physical
examination. Peripheral blood extraction will be per-
formed for analysis: hemogram, biochemistry assays, and
HLA study, and a negative pregnancy test (either in
urine or blood) is mandatory in case of women in child-
bearing age. The evaluation of the visceral involvement
of CD will be completed with a chest x-ray and electro-
cardiogram. The performance of other complementary
tests will be carried out according to the clinical investi-
gator’s decision, but they will not be considered neces-
sary for the inclusion of the patient.
3. Treatment phase
In this phase, the patient will be randomized to one of the
three arms of treatment, whose duration will be 60 days in-
dependently of the arm assigned. Initially, a baseline visit will
be performed in which the patient will be trained on how to
take the drug and identify AEs. After that, a total of four
scheduled visits will occur during the treatment period, at 7,
15, 28, and 60 days after treatment initiation. A summary of
these visits is presented in Table 3.
During this phase, any patient may consult spontan-
eously for the eventual occurrence of any AE. The deci-
sion to interrupt the treatment will be according to the
discretion of the clinical researcher treating the patient,
taking into account the severity, intensity, and extent of
these AEs. In addition, the patient may decide unilat-
erally to suspend or not the medication at any time dur-
ing the treatment period.
4. Follow-up phase
Once the patient has taken the last dose of treatment,
which may be at the end of the therapeutic scheme (day
60), when a severe AE that obliges the patient to sus-
pend the medication occurs, or when the patient unilat-
erally decides to suspend the medication, this phase will
begin, and it will last up to 12 months after
randomization. The visit schedule of this phase is pre-
sented in Table 3.
SAEs and unblinding: care of patients with AEs
All AEs and other study outcomes in the randomization,
treatment, and follow-up periods will have to be re-
ported. In case of mild or moderate AEs, the administra-
tion of BNZ will be suspended temporarily according to
the clinical researcher’s decision. Symptomatic treatment
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will be provided to the patient according to the treating
physician.
It will be considered that a patient has finished the
study when he or she has completed the treatment and
follow-up phase (per-protocol principle). The study may
be interrupted in case of voluntary decision of the pa-
tient at any time if an AE forces interruption of the
treatment, if significant protocol violations occur, or if
the treating physician deems it would benefit the patient
(intention-to-treat principle).
Ethics and patient confidentiality
The protocol has been approved by national regulatory
agencies (in accordance with the ethical standards laid
down in the Declaration of Helsinki as revised in 2013), by
the institutional review boards for clinical research of all
participating institutions, and by the national ethics review
committees of the countries involved in the study (when
applicable). All patients provide written informed consent,
whereby the researcher will explain to each patient the na-
ture of the study; its purposes, procedures, expected dur-
ation, and the potential risks and benefits related to
participating; and any inconvenience that may occur.
Discussion
CD continues to be an infectious disease with one of the
highest disease burdens worldwide. Despite the modest
cure rates in adult chronic patients and its safety profile,
BNZ remains the best treatment option against the dis-
ease due to the lack of therapeutic alternatives [7]. Con-
ventional diagnostic methods for establishing cure rates
in chronic CD have marked inherent limitations; how-
ever, the use of more sensitive methods for parasite de-
tection, such as PCR, could provide a suitable tool for
follow-up assessment of treatment in patients with CD,
because detectable T. cruzi DNA in peripheral blood
samples after treatment end is considered a therapeutic
failure [31].
Table 3 Visit schedule
Selection visit









































x x x x x x x x x
Directed anamnesis x x x x x x x x x
Physical
examination
x x x x x x x x x
Pregnancy test x
Hematology x x x x x x




PK x x x
Serology x x





Adverse events x x x x x x
Randomization x
Study medication x x x x x
Abbreviations: EKG Electrocardiogram, HLA Human leukocyte antigen, PCR Polymerase chain reaction, PK Pharmacokinetics
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The currently used dose of BNZ is based on nonran-
domized studies that were carried out more than 50
years ago, and they have never been analyzed in clinical
trials. Moreover, there are no data regarding the rela-
tionship between dose and efficacy, because the great
majority of published experience (clinical trials and ob-
servational studies) has been with the standard dose.
Recent studies have brought to light interesting results
that point out different possibilities of treatment
schemes. On the basis of two PK studies, authors sug-
gested that current treatment regimens could be over-
dosed [19, 20]. One them extrapolated the idea
according to the lower concentration observed in treated
children that finally achieved cure. The other based the
conclusion on dosage regimen simulation under steady-
state conditions comparing the estimated concentration
with the optimal therapeutic accepted range. This hy-
pothesis has also been observed preclinically using an
in vivo model under the framework of the Berenice Pro-
ject (Benznidazol and Triazol Research Group for Nano-
medicine and Innovation on Chagas Disease). Results
obtained from the murine model led researchers to con-
clude that a dose of 40% of the total of the version used
as standard is comparable in efficacy.
At the same time, there is evidence of the opposite.
According to mechanism of action of BNZ, it seems that
the efficacy of the drug (and all nitroderivative drugs) is
concentration-dependent. To include an arm with higher
dose in a clinical trial could pose an increased risk of
toxicity. The clinical experience obtained through clin-
ical trials with higher doses of BNZ (400 mg/day) led to
the belief that higher dose is not associated with higher
frequency of AEs [23, 24].
In addition, the mechanisms underlying BNZ toxicity
are still not well understood. The production of several
metabolites in the enzymatic reduction of the drug, their
accumulation, and their interactions with cellular con-
stituents could be the main reasons for producing these
AEs [32, 33]. Some AEs of the drug have a certain tem-
poral pattern. For example, dermatological and digestive
manifestations usually tend to occur around day 10 of
treatment, while neurological events and arthritis appear
after day 40 of treatment, probably because they are re-
lated to the cumulative total dose and not to the serum
concentration [9]. Age and female sex have also been
considered as classic risk factor for AEs. However, there
remains an important lack of knowledge about the
mechanisms of toxicity [9, 10].
According to the duration of the treatment, two ap-
proaches were considered. Taking into account the cure
rates of patients with CD treated with shorter courses of
BNZ (those who had to interrupt the treatment because of
AEs), a shortened regimen has been incorporated. Finally, re-
searchers explored the possibility of including a new arm
with prolonged exposure. Unfortunately, due to the lack of
clinical published experience and the potential risk of go-
nadal toxicity and its effect over the pituitary–testicular axis,
that treatment arm was discarded [34, 35].
Another aspect that will be assessed is the genetic variabil-
ity of the parasite over the treatment response. The great
majority of randomized clinical trials have been conducted
in Argentinean or Bolivian patients, and scarce information
is available in other geographical regions. In any case, the
few existing data suggest an important effect of parasitic di-
versity in the treatment efficacy and response [17, 36].
Therefore, this clinical trial will evaluate the efficacy
and safety of different dosing regimens of BNZ com-
pared with the standard treatment scheme. Experimental
dosing regimens have been chosen on the basis of evi-
dence derived from previous studies, in which it has
been found that shorter-duration schemes and/or lower
dose with the same duration could achieve the same
cure rate. Moreover, higher doses could be used without
entailing a higher rate of AEs. The results of this clinical
trial will help to better identify the most adequate BNZ
regimen in terms of efficacy and safety for the treatment
of CD in the chronic phase.
The MULTIBENZ study is included within the Bere-
nice Project, founded by the European Commission and
initiated in September 2012. The aim of the Berenice
Project is to provide a new and cost-effective solution to
treat patients with CD in chronic phase and to develop
new drug formulations with trypanocidal activity. Its
main objective is to obtain a more effective, better toler-
ated, and cheaper treatment to cure CD. The results ob-
tained in the Berenice Project will upgrade European
competitiveness through the transformation of research
in the field of neglected infectious diseases.
Trial status
Recruitment was started in April 2018, and it is estimated to
be completed in all countries by August 2020. Protocol ver-
sion V1/ 05-12-2016.
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